• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.在白血病发生过程中,不同细胞类型对造血干细胞活性和 Nras G12D 信号的要求不同。
Cell Cycle. 2011 Sep 1;10(17):2836-9. doi: 10.4161/cc.10.17.17195.
2
Oncogenic Kras initiates leukemia in hematopoietic stem cells.致癌性Kras在造血干细胞中引发白血病。
PLoS Biol. 2009 Mar 17;7(3):e59. doi: 10.1371/journal.pbio.1000059.
3
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.从内源性基因座表达致癌性 NrasG12D 的小鼠中的造血作用和白血病发生。
Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.
4
Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.NRAS(G12D/+) 通过异常调节造血干细胞功能促进白血病发生。
Blood. 2013 Jun 27;121(26):5203-7. doi: 10.1182/blood-2012-12-475863. Epub 2013 May 17.
5
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.内源性致癌性 Nras 突变以剂量和细胞类型依赖的方式引发造血系统恶性肿瘤。
Blood. 2011 Jul 14;118(2):368-79. doi: 10.1182/blood-2010-12-326058. Epub 2011 May 17.
6
Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.Dnmt3a缺失与内源性Kras(G12D/+)协同作用,在白血病发生过程中调节造血干细胞和祖细胞的功能。
Leukemia. 2015 Sep;29(9):1847-56. doi: 10.1038/leu.2015.85. Epub 2015 Mar 24.
7
Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis.基础 RASGRP1 信号的增加增强了天然造血过程中的干细胞适应性。
Oncogene. 2020 Nov;39(45):6920-6934. doi: 10.1038/s41388-020-01469-8. Epub 2020 Sep 28.
8
Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.致癌性 Nras 对维持干细胞竞争力的干细胞具有双峰作用。
Nature. 2013 Dec 5;504(7478):143-147. doi: 10.1038/nature12830. Epub 2013 Nov 27.
9
Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.Notch1 基因突变靶向 KRAS G12D 表达的 CD8+细胞,并有助于其白血病转化。
J Biol Chem. 2013 Jun 21;288(25):18219-27. doi: 10.1074/jbc.M113.475376. Epub 2013 May 14.
10
Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.致癌性Kras诱导的白血病发生:造血干细胞作为初始靶点,谱系特异性祖细胞作为最终白血病转化的潜在靶点。
Blood. 2009 Feb 5;113(6):1304-14. doi: 10.1182/blood-2008-01-134262. Epub 2008 Dec 9.

引用本文的文献

1
Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia.青少年骨髓单核细胞白血病疾病模型的进展与展望
Med Oncol. 2024 Dec 9;42(1):25. doi: 10.1007/s12032-024-02549-5.
2
Activity of trametinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory RAS pathway-mutated hematologic malignancies.曲美替尼作为复发或难治性RAS通路突变血液系统恶性肿瘤患者异基因造血干细胞移植后维持治疗的活性。
Ann Hematol. 2025 Feb;104(2):1295-1301. doi: 10.1007/s00277-024-06046-7. Epub 2024 Oct 19.
3
[Genetic characteristics and prognostic values of RAS mutations in patients with myelofibrosis].[骨髓纤维化患者RAS突变的遗传特征及预后价值]
Zhonghua Xue Ye Xue Za Zhi. 2020 Dec 14;41(12):989-995. doi: 10.3760/cma.j.issn.0253-2727.2020.12.004.
4
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.NrasQ61R 和 MYC 转基因在生发中心 B 细胞中的表达可诱导小鼠发生高度恶性多发性骨髓瘤。
Blood. 2021 Jan 7;137(1):61-74. doi: 10.1182/blood.2020007156.
5
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.Stat5对于由Nf1缺陷引发的骨髓增殖性肿瘤的发生和维持至关重要。
Haematologica. 2016 Oct;101(10):1190-1199. doi: 10.3324/haematol.2015.136002. Epub 2016 Jul 14.
6
Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.致癌性NRAS在人脐带血干细胞/祖细胞中过度激活多种信号通路,并在体内促进髓单核细胞增殖。
Am J Transl Res. 2015 Oct 15;7(10):1963-73. eCollection 2015.
7
Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.通过多重聚合酶链反应和新一代测序剖析骨髓增殖性肿瘤中的基因组畸变
PLoS One. 2015 Apr 20;10(4):e0123476. doi: 10.1371/journal.pone.0123476. eCollection 2015.
8
Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.Ras/Raf/MEK/ERK 通路在儿童急性淋巴细胞白血病中的激活及其治疗靶点。
Front Oncol. 2014 Jun 24;4:160. doi: 10.3389/fonc.2014.00160. eCollection 2014.
9
Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.MEK 和 JAK 联合抑制消除了小鼠骨髓增生性肿瘤。
J Clin Invest. 2014 Jun;124(6):2762-73. doi: 10.1172/JCI74182. Epub 2014 May 8.
10
Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.NRAS(G12D/+) 通过异常调节造血干细胞功能促进白血病发生。
Blood. 2013 Jun 27;121(26):5203-7. doi: 10.1182/blood-2012-12-475863. Epub 2013 May 17.

本文引用的文献

1
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.内源性致癌性 Nras 突变以剂量和细胞类型依赖的方式引发造血系统恶性肿瘤。
Blood. 2011 Jul 14;118(2):368-79. doi: 10.1182/blood-2010-12-326058. Epub 2011 May 17.
2
Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.内源性致癌性 Nras 突变在慢性粒单核细胞白血病小鼠模型中促进粒细胞/单核细胞前体细胞中异常的 GM-CSF 信号传导。
Blood. 2010 Dec 23;116(26):5991-6002. doi: 10.1182/blood-2010-04-281527. Epub 2010 Oct 4.
3
Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.致癌性Kras诱导的白血病发生:造血干细胞作为初始靶点,谱系特异性祖细胞作为最终白血病转化的潜在靶点。
Blood. 2009 Feb 5;113(6):1304-14. doi: 10.1182/blood-2008-01-134262. Epub 2008 Dec 9.
4
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.致癌性K-ras从其内源启动子的条件性表达会诱发骨髓增殖性疾病。
J Clin Invest. 2004 Feb;113(4):528-38. doi: 10.1172/JCI20476.
5
Inducible gene targeting in mice.小鼠中的诱导型基因靶向
Science. 1995 Sep 8;269(5229):1427-9. doi: 10.1126/science.7660125.

在白血病发生过程中,不同细胞类型对造血干细胞活性和 Nras G12D 信号的要求不同。

Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.

机构信息

McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, USA.

出版信息

Cell Cycle. 2011 Sep 1;10(17):2836-9. doi: 10.4161/cc.10.17.17195.

DOI:10.4161/cc.10.17.17195
PMID:21857161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3218596/
Abstract

We previously showed that widespread expression of Nras G12D/G12D from its endogenous locus in mice leads to an acute myeloproliferative disease (MPD) with a complete penetrance, whereas bone marrow-specific expression of Nras G12D/G12D in recipient mice did not result in sustained MPD phenotypes but 100% penetrant acute T-cell lymphoblastic leukemia/lymphoma (TALL). Such a phenotypic switch also is seen in the case of endogenous oncogenic Kras. Two possibilities might account for this observation and they are not necessarily mutually exclusive. First, the MPD phenotypes in primary Nras G12D/G12D mice might be a transient phenomenon attributable to microenvironmental factors that do not necessarily imply the potential for long-term maintenance in a hematopoietic-cell autonomous manner. Second, it is likely that MPD phenotypes are maintained by genetically altered hematopoietic stem cells (HSCs). Nras G12D/G12D signaling might substantially alter HSC behaviors (e.g. induce their proliferative exhaustion) so that these HSCs no longer sustain MPD phenotypes to a lethal stage in recipient mice. Here, we show some preliminary results to support the second hypothesis. Our results suggest that different lineages of hematopoietic cells might have differential requirements of HSC activity and Nras G12D signaling during leukemogenesis.

摘要

我们之前曾表明,在小鼠中从其内源基因座广泛表达 Nras G12D/G12D 会导致完全穿透的急性骨髓增生性疾病(MPD),而在受者小鼠中骨髓特异性表达 Nras G12D/G12D 则不会导致持续的 MPD 表型,但会导致 100%穿透的急性 T 细胞淋巴母细胞白血病/淋巴瘤(TALL)。这种表型转换也发生在内源致癌 Kras 的情况下。有两种可能性可以解释这种观察结果,它们不一定相互排斥。首先,原发性 Nras G12D/G12D 小鼠中的 MPD 表型可能是一种短暂现象,归因于微环境因素,这些因素不一定意味着以造血细胞自主方式长期维持的潜力。其次,MPD 表型可能由遗传改变的造血干细胞(HSC)维持。Nras G12D/G12D 信号可能会极大地改变 HSC 的行为(例如,诱导其增殖耗尽),以至于这些 HSC 不再在受者小鼠中维持 MPD 表型至致死阶段。在这里,我们展示了一些初步结果来支持第二个假设。我们的结果表明,在白血病发生过程中,不同的造血细胞谱系可能对 HSC 活性和 Nras G12D 信号有不同的要求。